SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 1,181.63 |
| Enterprise Value ($M) | 456.35 |
| Book Value ($M) | 747.00 |
| Book Value / Share | 11.25 |
| Price / Book | 1.58 |
| NCAV ($M) | 701.82 |
| NCAV / Share | 10.57 |
| Price / NCAV | 1.68 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.21 |
| Return on Assets (ROA) | -0.18 |
| Return on Equity (ROE) | -0.19 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 18.91 |
| Current Ratio | 18.91 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 747.16 |
| Assets | 792.34 |
| Liabilities | 45.34 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 7.02 |
| Operating Income | -195.08 |
| Net Income | -157.86 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -157.78 |
| Cash from Investing | -290.13 |
| Cash from Financing | 441.45 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 7.30 | -12.07 | |
| 13G | Commodore Capital Lp | 5.00 | ||
| 13G/A | Kynam Capital Management, LP | 7.63 | 68.48 | |
| 13G | Price T Rowe Associates Inc /md/ | 5.40 | ||
| 13G/A | Fmr Llc | 7.30 | -19.37 | |
| 13G/A | Eventide Asset Management, Llc | 5.03 | -8.21 | |
| 13G/A | Rtw Investments, Lp | 0.00 | -100.00 | |
| 13G/A | Point72 Asset Management, L.P. | 2.50 | -38.90 | |
| 13G/A | Polar Capital Holdings Plc | 4.09 | -13.54 | |
| 13G/A | Wellington Management Group Llp | 13.94 | 42.72 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 91,642 | 370,688 | 24.72 | |
| 281,034 | 845,161 | 33.25 | |
| 208,052 | 660,521 | 31.50 | |
| 120,695 | 575,841 | 20.96 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CGTX – Cognition Therapeutics, Inc. | CING – Cingulate Inc. |
| CKPT – Checkpoint Therapeutics, Inc. | CLNN – Clene Inc. |
| CLRB – Cellectar Biosciences, Inc. |